Kancera AB | Income Statement

Fiscal year is January-December. All values SEK Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
1,813.00
470.00
282.00
308.00
113.00
Cost of Goods Sold (COGS) incl. D&A
1,239.00
1,330.00
1,163.00
1,180.00
1,242.00
Gross Income
574.00
860.00
881.00
872.00
1,129.00
SG&A Expense
10,978.00
15,235.00
24,014.00
21,410.00
55,277.00
EBIT
10,404.00
16,095.00
24,895.00
22,282.00
56,406.00
Non Operating Income/Expense
3,000.00
71.00
5,202.00
88.00
119.00
Interest Expense
15.00
-
-
-
-
Pretax Income
7,418.00
15,979.00
19,612.00
22,308.00
56,198.00
Consolidated Net Income
7,418.00
15,979.00
19,612.00
22,308.00
56,198.00
Net Income
7,418.00
15,979.00
19,612.00
22,308.00
56,198.00
Net Income After Extraordinaries
7,418.00
15,979.00
19,612.00
22,308.00
56,198.00
Net Income Available to Common
7,418.00
15,979.00
19,612.00
22,308.00
56,198.00
EPS (Basic)
0.18
0.23
0.16
0.17
0.37
Basic Shares Outstanding
40,849.90
69,688.20
119,711.00
130,638.40
153,707.80
EPS (Diluted)
0.18
0.23
0.16
0.17
0.37
Diluted Shares Outstanding
40,849.90
69,688.20
119,711.00
130,638.40
153,707.80
EBITDA
9,695.00
15,071.00
23,806.00
21,165.00
55,238.00
Non-Operating Interest Income
1.00
187.00
81.00
62.00
89.00

About Kancera AB

View Profile
Address
Karolinska Institutet Science Park
Solna AB 171 48
Sweden
Employees -
Website http://www.kancera.com
Updated 09/14/2018
Kancera AB engages in the research, development, and sale of drug candidate to pharmaceutical companies. Its portfolio includes Fractalkine, ROR inhibitors, HDAC6, and PFKFB3 projects. The company was founded by Hakan Mellstedt on April 28, 2010 and is headquartered in Solna, Sweden.